IN8BIO - Key Persons

Job Titles:

• Chairman
• Member of Our Board of Directors

Alan S. Roemer has served as chairman and a member of our board of directors since September 2020. Mr. Roemer has served on the board and as the chair of the audit committee of board of NexImmune, Inc., a biotechnology company, since March 2017 and as the chair of the board of UTILITY therapeutics Ltd., a private biotechnology company, since March 2020. Mr. Roemer was the founding member and Senior Vice President of Roivant Sciences, Inc., a private biopharmaceutical company, from May 2014 to August 2019, where he held various senior management roles responsible for finance, operations and corporate development. From March 2015 to August 2015, he also served as principal financial and accounting officer of Axovant Sciences Ltd., a public biopharmaceutical company, and chief financial officer of its wholly owned subsidiary, Axovant Sciences, Inc. Mr. Roemer also served as a member of the board of directors of SomPharmaceuticals SA, a private biopharmaceutical company, from August 2012 to May 2016, until its acquisition by Amryt Pharma plc. Prior to Axovant, Mr. Roemer served in various roles, including managing director of the Trout Group LLC and Trout Capital LLC from 2009 to 2014, chief financial officer and treasurer of Zelos Therapeutics, Inc. from 2008 to 2009, and vice president of Pharmasset, Inc. 1998 to 2008, which was subsequently acquired by Gilead Sciences, Inc. Mr. Roemer has also served as a member of the business advisory board of Envisagenics, Inc., a private artificial intelligence company, since March 2020, and a member of the Board of Trustees of the Helene Fuld College of Nursing since June 2014. Mr. Roemer received a B.S. in Business Administration from Georgetown University and his MBA and MPH degrees from Emory University's Goizueta Business School and Rollins School of Public Health.

Job Titles:

• Professor in Cancer Gene Therapy and Director, Clinical Cell and Vaccine Production Facility - University of Pennsylvania

Job Titles:

• Professor at the University of Kiel, Director of the Institute of Immunology

Job Titles:

• Director
• Member of Our Board of Directors

Dr. Corinne Epperly has served as a member of our Board of Directors since December 2023. She brings 20 years of experience as a physician and scientist blending medicine and business with a proven track record in oncology drug development. Most recently Dr. Epperly served as the Chief Operating Officer (COO) of CARGO Therapeutics, a clinical-stage, next-generation CAR-T cell therapy company. Here she played a pivotal role in the company's formation, overseeing its growth from day-one through significant financing milestones including the successful $200 million Series A funding round. At CARGO, her responsibilities included corporate strategy, business development, finance, corporate operations, and early commercial and pipeline planning. Prior to CARGO, Dr. Epperly was Senior Vice President of Strategy and Operations at Iovance Biotherapeutics and also served as the US COO at VBL Therapeutics. Previously Dr. Epperly spent seven years at Bristol Myers Squibb where she played instrumental leadership roles in driving the launches of OPDIVO® (nivolumab) and YERVOY® (ipilimumab) across multiple tumor indications and led global M&A transactions such as the acquisition of Amylin Pharmaceuticals with diabetes partner AstraZeneca and subsequent sale. Earlier in her career, Dr. Epperly worked at Goldman Sachs where she served as an Equity Analyst in Global Pharmaceutical and Biotechnology Investment Research. Dr. Epperly also serves on the Board of Sastra Cell Therapy, a private cell therapy company, and previously on the Board of AVEO Oncology prior to its acquisition by LG Chem. She holds a Bachelor's degree in Biochemistry and Biology from the University of Virginia, a Doctorate of Medicine and a Masters of Public Health from the University of North Carolina at Chapel Hill.

Job Titles:

• Director
• Member of Our Board of Directors

Emily Wang Fairbairn has served as a member of our board of directors since July 2021. From 2018, she has also served as the Chair of the Board at Movano. Ms. Fairbairn has spent the majority of her career in executive leadership and management positions and as a seasoned investor and mentor to early-stage companies. In 1999, Ms. Fairbairn was Co-Founder and CEO of Ascend Capital, a multi-billion-dollar hedge fund, which she ran until 2018. The firm focused on managing assets for institutional clients such as pensions, endowments, and public companies. Prior to Ascend Capital, she spent a decade building a successful practice of equity portfolio construction and financial planning for high net worth clients for Merrill Lynch. Today, Ms. Fairbairn is an active investor, and since 2017 serving on the funding board of the MIT Sandbox Fund to mentor aspiring entrepreneurs. She is also a dedicated advocate of funding research for a realizable diagnostic and cure for Lyme+, which effects around 500,000 people annually in the U.S. Emily holds a Bachelor of Science degree from California State Polytechnic University in Chemical Engineering.

Job Titles:

• Vice President, Head of Investor Relations & Corporate Communications

Glenn has served as our VP, Head of Investor Relations and Corporate Communications since April 2024. Dr. Schulman has over 20 years of experience in the biotech industry focused on investor and public relations, corporate strategy, medical and corporate communications. Prior to joining IN8bio, Glenn was responsible for leading IR and Corporate Communications at multiple NASDAQ-listed companies including ProKidney Corp., Aurinia Pharmaceuticals, Achillion Pharmaceuticals, and CuraGen Corp. Dr. Schulman's expertise spans the drug development life cycle from discovery through the commercialization of novel small molecule, biologic, and cell therapy candidates. Dr. Schulman also worked as a pharmacist in both hospital and retail settings for 15 years. Dr. Schulman attained his bachelor's degree from Philadelphia College of Pharmacy and his Doctor of Pharmacy degree from Rutger's University. Dr. Schulman received his Master Public Health, Health Management degree from Yale University.

Job Titles:

• Director
• Member of Our Board of Directors

Dr. Jeremy Graff has served as a member of our board of directors since May 2023. With over two decades of experience in drug development and leadership within the biotechnology and pharmaceutical sectors, Dr. Graff currently serves as the Chief Scientific Officer at IMV Inc, an early-stage Canadian biotechnology company. There, he oversees the company's research programs and the development of its cutting-edge cancer vaccine platform. Previously, Dr. Graff held C-level and senior executive positions at various biotechnology companies. During his nearly 17-year tenure at Eli Lilly and Company, Dr. Graff identified and validated new molecular targets for advanced cancers, working alongside the clinical development team to establish and lead the translational oncology group. This group supported and advanced the 31 clinical assets in Eli Lilly's oncology portfolio at the time. Dr. Graff also serves as a member of the Board of Trustees for the Wood Hudson Cancer Research Laboratory and is on the Scientific Advisory Board of Avicenna Biosciences, Inc. He completed a post-doctoral fellowship at the Johns Hopkins University School of Medicine.

Job Titles:

• Chief Operating Officer

Kate has served as our Chief Operating Officer since December 2021. She previously served as the VP and AVP of Operations and Innovation since August 2020. She has over 15 years of extensive expertise in early-stage biotechnology and company development, including conducting scientific research, managing intellectual property (IP) strategy, overseeing strategic & business development and managing company operations including corporate strategy, partnering and team buildout. She joined from Curadigm, a Cambridge, MA-based biotechnology company where she held various senior roles, most recently as Chief Business Officer. She helped lead Curadigm's spin-out from Nanobiotix and developed collaborations and partnerships around a novel platform to increase therapeutic bioavailability. Crain's New York Business recognized Kate as one of the top women in tech in 2019. Previously, she served as the Director of Scientific Affairs at Filament BioSolutions, developing therapeutics in oncology supportive care, specifically for oral mucositis. She is a scientific and business advisor to Immunovent, a New York-based biotechnology company she co-founded and previously served as its Chief Scientific Officer. Dr. Rochlin also serves as an executive board member to The Solution Lab, a New York-based non-profit organization dedicated to providing Ph.D. and MBA students with real-world consulting experiences. Dr. Rochlin earned a Ph.D. in Molecular Biology and Genetics from Weill Cornell Medical College, conducting research at Sloan Kettering Institute, and a BA in Biology from the University of Pennsylvania.

Job Titles:

• Chief Scientific Officer
• Co - Founder
• Executive Vice President

Job Titles:

• Director
• Member of Our Board of Directors

Luba Greenwood has served as a member of our board of directors since July 2021. Ms. Greenwood is a veteran biotech, pharmaceutical, tech, and life science tools investor and company builder. Luba serves as the Managing Partner of the Dana Farber Cancer Institute Venture Fund, Binney Street Capital, which she has built and launched. She has also co-founded Cathay Health, where she serves as the Managing Partner. She is a professor at Harvard University in the School of Engineering and Applied Sciences. Previously she has served in leadership roles at Google Life Sciences and as Vice President of Global Business Development and Mergers & Acquisitions at Roche, where she established and led the East Coast Innovation Hub. She has co-founded biotech and digital health companies in the immunotherapy, AI/ML, women's health and microbiome space, including IN8Bio and Luca Biologics. She serves on numerous boards, including the Massachusetts Biotechnology Council (MassBio), Kojin, Brooklyn ImmunoTherapeutics, BenchSci, and Entrinsic Health, and has served as a Senior Advisor to the CEO of the Dana-Farber Cancer Institute as well as the Wyss Center for Bio and Neuroengineering. She is a Thought Leader for the New England Journal of Medicine (NEJM) Catalyst, and a Founder of the Pharma Digital Health Roundtable. She has served on numerous non-profit boards including the Longwood Symphony Orchestra, advised on global Covid response efforts, including Covid SafePaths, and serves on Investor Committee for the National Cancer Institute. Luba is a former litigator and regulatory, policy, and IP expert, having started her career at Wilmer Cutler Pickering Hale and Dorr. She is a recipient of several awards and honors for her work in the community, including the Science Club for Girls Catalyst Award for her commitment to advocating for women in science and technology.

Job Titles:

• Director of Cellular Immunotherapy, Cancer Center - Massachusetts General Hospital

Job Titles:

• Vice President, Accounting

Michael has served as our Vice President, Accounting since December 2023. Mr. McNamara has over 15 years of experience in the finance and accounting operations of publicly-traded, clinical-stage life science companies. Most recently, he served as Executive Director of Finance for LAVA Therapeutics N.V., and prior to that as Executive Director of Finance for Marinus Pharmaceuticals, Inc. and Corporate Controller for Polymedix, Inc. Mr. McNamara began his career in public accounting at Deloitte & Touche LLP, serving audit clients in the retail, technology and life science industries. Mr. McNamara holds a bachelor's of science degree in Accounting and a bachelor's of science degree in Finance from Villanova University.

Job Titles:

• Director
• Director of the Hematopoietic Cellular Therapy Program

Dr. Bishop is the Director of the Hematopoietic Cellular Therapy Program, Director of the David and Etta Jonas Center for Cellular Therapy, and Professor of Medicine at the University of Chicago. Dr. Bishop joined the National Cancer Institute in March 1999 to serve as the Clinical Head of the Stem Cell Transplantation Program. In 2003, he received the National Institutes of Health Distinguished Clinical Teacher Award. He received tenure as Senior Investigator at NIH in 2007. In 2009 he organized and co-chaired the First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation. In 2011 Dr. Bishop's was appointed as Head of the Hematologic Malignancies Section in the Division of Hematology and Oncology at the Medical College of Wisconsin/Froedtert Hospital in Milwaukee. In 2012, Dr. Bishop was recruited to serve as the director of the University of Chicago Hematopoietic Stem Cell Transplantation Program and was appointed Professor of Medicine in the Division of Hematology and Oncology, Department of Medicine at the University of Chicago. In 2013, Dr. Bishop was named a Bucksbaum Institute for Clinical Excellence Master Clinician. In 2020, Dr. Bishop was named the Director of the David and Etta Jonas Center for Cellular Therapy at the University of Chicago. Dr. Bishop's research focuses on the development and conducting of novel clinical trials in hematopoietic stem cell transplantation and cellular therapy. Particular areas of interest include the therapeutic use of T cells to treat hematologic malignancies and solid tumors. In addition, his research program is focused on methods to prevent and treat recurrent disease following hematopoietic stem cell transplantation, with a primary focus on B-cell malignancies, as well as myeloma and leukemia. Dr. Bishop has authored or co-authored over 200 peer-reviewed articles in journals such as New England Journal of Medicine, Lancet, Journal of Clinical Oncology, and Blood and over 35 book chapters relative to the fields of hematologic malignancies, hematopoietic stem cell transplantation, and cellular therapy. He serves as a reviewer and on the editorial boards of numerous scientific journals including New England Journal of Medicine, Journal of Clinical Oncology, Blood, Journal for ImmunoTherapy of Cancer, and Biology of Blood and Marrow Transplantation. Dr. Bishop received his M.D. from the University of Illinois in 1985. He completed clinical training in internal medicine at Northwestern University in 1988 and a fellowship in hematology and oncology at Loyola University Medical Center in 1991. He was an assistant professor of medicine at the University of Kentucky Medical Center from 1991 to 1992 and an associate professor of medicine at the University of Nebraska Medical Center from 1992 to 1999, where he served as director of the Leukemia and Allogeneic Stem Cell Transplantation Programs.

Job Titles:

• Chief Financial Officer

Patrick McCall has served as our Chief Financial Officer since February 2021. Mr. McCall brings more than 16 years of experience in global finance, accounting and capital raising. Prior to joining IN8bio, Mr. McCall was Vice President of Finance at Turnstone Biologics Corp. an international clinical stage biotechnology company, focused on cancer immunotherapies. There he assisted in raising several rounds of financing, a large collaboration with a global pharmaceutical company, an acquisition in the immunotherapy space and led the build out of the company's finance and accounting functions. Prior to that Mr. McCall was the Corporate Controller at Catalyst Biosciences, a publicly traded, clinical stage biopharmaceutical company focused on developing hemophilia treatments. While at Catalyst Biosciences, Mr. McCall was part of the team that successfully completed the company's initial public offering and he was responsible for leading the firm's SEC reporting, accounting, financial planning & analysis and procurement functions. Previously, he spent 11 years in a variety of finance, accounting, and operational roles at companies such as Apple, Chubb and the accounting firm Deloitte as an auditor. Mr. McCall is an active Certified Public Accountant (CPA) and holds an M.B.A from Cornell University and a B.S. in Accounting from Drexel University.

Job Titles:

• Director

Job Titles:

• Vice President, Clinical Development - EQRx

Job Titles:

• Vice President, Clinical Operations

Stacey has served as our VP, Clinical Operations since March 2022. She brings more than 30 years of diverse clinical and operations experience to IN8bio, ranging from CROs and small/medium pharma to start-up companies. Prior to joining In8Bio, Ms. Bilinski was the global senior director of clinical operations at Taiho Oncology Inc, where she ran the life cycle management or the Lonsurf program as well as numerous first in-human and early phase studies. Previously, she was Executive Director of clinical operations at Onconova, where she directed clinical operations for programs in MDS, pancreatic, and head and neck cancer. Earlier, Ms. Bilinski spent 16 years working at CROs in clinical operations. In these roles, she managed clinical development programs for rare diseases as well as cardiovascular compounds in both early and late-stage development. Ms. Bilinski has a bachelor's degree from Rutgers University.

Job Titles:

• Director

Job Titles:

• Chief Medical Officer

Trishna has served as our Chief Medical Officer since November 2021. She brings over a decade of experience in clinical drug development including experience with antibody drug conjugates and immunotherapy. Dr Goswami most recently served as Vice President, Clinical Development at Gilead Sciences, Inc., which she joined through its acquisition of Immunomedics in 2020. At Immunomedics she led a team that secured accelerated approval of Trodelvy® in bladder cancer and contributed to securing full FDA approval in triple-negative breast cancer. Prior to Gilead/Immunomedics, she served as a Senior Medical Director at Stemline Therapeutics, Inc. where she oversaw the development of multiple hematologic assets and helped secure approval of ELZONRIS® (tagraxofusp). Dr. Goswami was previously at MedImmune, then AstraZeneca/MedImmune post-acquisition, where she managed biologics development for hematologic indications, launching the first phase 3 trial in an oncology indication at MedImmune. At AstraZeneca, Dr. Goswami also participated in the development of IMFINZI® (durvalumab) and tremelimumab. Before her career in industry, Dr. Goswami served as Assistant Professor, Department of Medicine, Division of Hematology/Oncology at the University of Maryland. She is an author of multiple publications during her tenure in academia and industry. Dr. Goswami earned her M.D. from Drexel University College of Medicine, completed her postgraduate training in internal medicine and hematology/oncology at Georgetown University Hospital and completed her MBA from Smith School of Business at the University of Maryland.

Job Titles:

• Vice President, Regulatory Affairs

Urvashi has served as our VP Regulatory Affairs since March 2022. Dr. Patel has 18 years of experience in pharmaceutical drug development, mainly in Regulatory Affairs and Quality Assurance. Prior to joining IN8Bio, Dr. Patel worked for Precision Medicine where she helped emerging small biotech companies with their regulatory and quality needs and most recently with WindMIL Therapeutics where she was responsible for regulatory oversight as well as quality and compliance. Dr. Patel's expertise spans from early development to post-marketing. After completing her graduate studies at Stanford University, Dr. Patel has worked on several immunotherapies in both the small biotechnology and large pharmaceutical companies, including Janssen Pharmaceuticals. Dr. Patel has a Ph.D. in Cell Biology from Stanford University and a B.A. from UC Berkely.

Job Titles:

• Director, President, CEO, and Co - Founder